- Home
- Publications
- Publication Search
- Publication Details
Title
Lipid Lowering Drugs: Present Status and Future Developments
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 23, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-11
DOI
10.1007/s11883-021-00918-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
- (2020) Shizuya Yamashita et al. Current Atherosclerosis Reports
- Familial combined hypolipidemia
- (2020) Marcello Arca et al. CURRENT OPINION IN LIPIDOLOGY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia
- (2020) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
- (2020) Peter Sever et al. European Journal of Preventive Cardiology
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation
- (2020) Johan G. Schnitzler et al. CIRCULATION RESEARCH
- Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
- (2020) Federica Fogacci et al. Current Atherosclerosis Reports
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical approach to the inflammatory etiology of cardiovascular diseases
- (2020) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- (2020) Robert P. Giugliano et al. STROKE
- Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
- (2020) Stephen D. Wiviott et al. JAMA Cardiology
- Meta-analysis of the Safety and Efficacy of Bempedoic Acid
- (2020) Muhammad U. Khan et al. AMERICAN JOURNAL OF CARDIOLOGY
- Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial)
- (2020) Adam J. Nelson et al. AMERICAN JOURNAL OF CARDIOLOGY
- Preventive Cardiology and Risk Assessment: Beyond LDL
- (2020) Amit Goyal et al. Current Atherosclerosis Reports
- Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies
- (2020) Julia Brandts et al. CURRENT OPINION IN LIPIDOLOGY
- Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance
- (2020) Rene C. Adam et al. JOURNAL OF LIPID RESEARCH
- Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
- (2020) Ning Kam et al. PHARMACOECONOMICS
- Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
- (2020) Konstantinos C Koskinas et al. European Journal of Preventive Cardiology
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
- (2020) Maciej Banach et al. JAMA Cardiology
- Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
- (2020) Maria Francesca Greco et al. Journal of Clinical Medicine
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance
- (2020) Stephen J Nicholls et al. AMERICAN HEART JOURNAL
- A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects
- (2020) Mariko Harada-Shiba et al. ATHEROSCLEROSIS
- No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels
- (2020) Kang H. Zheng et al. ATHEROSCLEROSIS
- LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase
- (2020) Liya Wu et al. CIRCULATION RESEARCH
- Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
- (2020) José Tuñón et al. EUROPEAN HEART JOURNAL
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
- (2020) Harold E. Bays et al. Journal of Clinical Lipidology
- Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
- (2020) Michael J. Domanski et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ApoCIII: A multifaceted protein in cardiometabolic disease
- (2020) D’Erasmo Laura et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
- (2020) Chie Iitake et al. Cardiovascular Diabetology
- Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events
- (2020) Garima Sharma et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evinacumab in Patients with Refractory Hypercholesterolemia
- (2020) Robert S. Rosenson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mendelian Randomization Study of ACLY and Cardiovascular Disease
- (2019) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
- (2019) Marja-Riitta Taskinen et al. Current Atherosclerosis Reports
- Statin therapy increases lipoprotein(a) levels
- (2019) Sotirios Tsimikas et al. EUROPEAN HEART JOURNAL
- Targeting RNA to lower triglycerides: long strides from short molecules
- (2019) Arman Qamar et al. EUROPEAN HEART JOURNAL
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
- (2019) Don P. Wilson et al. Journal of Clinical Lipidology
- Recent advances in synthetic pharmacotherapies for dyslipidaemias
- (2019) Cesare R Sirtori et al. European Journal of Preventive Cardiology
- PCSK9 inhibition and inflammation: A narrative review
- (2019) Massimiliano Ruscica et al. ATHEROSCLEROSIS
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
- (2019) Christie M Ballantyne et al. European Journal of Preventive Cardiology
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. ATHEROSCLEROSIS
- Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
- (2019) Jenny E. Kanter et al. JOURNAL OF CLINICAL INVESTIGATION
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES
- (2019) C. Macchi et al. PHARMACOLOGICAL RESEARCH
- HDL therapy today: from atherosclerosis, to stent compatibility to heart failure
- (2019) C.R. Sirtori et al. ANNALS OF MEDICINE
- Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
- (2019) Nicholas A. Marston et al. CIRCULATION
- Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial
- (2019) Amy Damask et al. CIRCULATION
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
- (2019) Michael Szarek et al.
- Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
- (2019) Peter R Sinnaeve et al. EUROPEAN HEART JOURNAL
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- (2019) Anne C. Goldberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
- (2019) Pierre Amarenco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography
- (2019) Suvasini Lakshmanan et al. CARDIOVASCULAR RESEARCH
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
- (2019) J. Wouter Jukema et al. CIRCULATION
- Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
- (2019) William E Boden et al. EUROPEAN HEART JOURNAL
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Update on the Impact of Omega 3 Fatty Acids on Inflammation, Insulin Resistance and Sarcopenia: A Review
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
- (2018) Julian C. van Capelleveen et al. Journal of Clinical Lipidology
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
- (2018) Yunosuke Matsuura et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
- (2018) Peter Willeit et al. LANCET
- FISHing for the Miracle of Eicosapentaenoic Acid
- (2018) John J.P. Kastelein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings
- (2017) Nicola Ferri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
- (2017) Geoffrey A. Preidis et al. JOURNAL OF CLINICAL INVESTIGATION
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- (2017) Vanessa Dubois et al. JOURNAL OF CLINICAL INVESTIGATION
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels
- (2017) Sumeet A Khetarpal et al. NATURE MEDICINE
- Hypertriglyceridaemia and risk of coronary artery disease
- (2017) Željko Reiner Nature Reviews Cardiology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis
- (2017) Danish Saleheen et al. Lancet Diabetes & Endocrinology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular DiseaseHighlights
- (2016) Eberhard Roeseler et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
- (2016) Ozlem Bilen et al. Current Atherosclerosis Reports
- Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
- (2016) Changting Xiao et al. DIABETES
- Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- (2016) Stephen L. Pinkosky et al. Nature Communications
- Technologies for controlled, local delivery of siRNA
- (2015) Samantha M. Sarett et al. JOURNAL OF CONTROLLED RELEASE
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
- (2015) Viktoria Gusarova et al. JOURNAL OF LIPID RESEARCH
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III: From Pathophysiology to Pharmacology
- (2015) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The pharmacology of statins
- (2014) Cesare R. Sirtori PHARMACOLOGICAL RESEARCH
- Integrated physiology and systems biology of PPARα
- (2014) Sander Kersten Molecular Metabolism
- Mechanisms of Action of (n-3) Fatty Acids
- (2012) Philip C. Calder JOURNAL OF NUTRITION
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
- (2008) Esther M. M. Ooi et al. CLINICAL SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started